SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
Sign Up to like & getrecommendations! Published in 2019 at "Cell metabolism"
DOI: 10.1016/j.cmet.2019.08.015
Abstract: Hess et al. quantified circulating aldehyde dehydrogenase-expressing (ALDHhi) cell subsets in people with T2DM given either empagliflozin (EMPA) or placebo. EMPA treatment increased circulating pro-angiogenic CD133+ progenitor cells, decreased pro-inflammatory ALDHhi granulocyte precursors, and increased ALDHhi… read more here.
Keywords: progenitor cells; empagliflozin increases; inhibition empagliflozin; increases circulating ... See more keywords